Enfermedad pulmonar intersticial asociada a esclerosis sistémica (EPI-ES)
Understanding Diagnostic Pathways in Systemic Sclerosis and Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD)
Assassi S et al.
Factors Prognostic of Greater Decline in Forced Vital Capacity in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD): Data from the Placebo Group of the SENSCIS Trial
Kuwana M et al.
Decline in Forced Vital Capacity in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD) with and without Gastroesophageal Reflux Disease: Further Analyses of the SENSCIS Trial
Highland KB et al.
Changes in Imaging Markers in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD) Treated with Nintedanib: Sub-Study of the SENSCIS Trial
Humphries S et al.
Continued Treatment with Nintedanib in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD): Interim Analysis of SENSCIS-ON
Allanore Y et al.
Drug-Drug Interaction Study of Nintedanib (Ofev) and the Combination of Ethinylestradiol and Levonorgestrel (Microgynon) in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD)
Vonk MC et al.
